Yüklüyor......
Access to Novel Drugs for Non‐Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis
BACKGROUND: Treatment of non‐small cell lung cancer (NSCLC) improved substantially in the last decades. Novel targeted and immune‐oncologic drugs were introduced into routine treatment. Despite accelerated development and subsequent drug registrations by the European Medicinal Agency (EMA), novel dr...
Kaydedildi:
| Yayımlandı: | Oncologist |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley & Sons, Inc.
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7066717/ https://ncbi.nlm.nih.gov/pubmed/32162818 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0523 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|